Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Impact of HER2 heterogeneity on treatment response of early-stage HER2positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab
ESM 1 (download DOC (DOC 2.01 MB) Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
F Overall Sample PC1 Control Chart
(2021) 65(12):e2100163
Its recommended used range is 0.3-3%
doi: 10.1002/ajh.21959 46 HarnanSRenSGomersallTEverson-HockESSuttonADhanasiriSet al
US$ 24.20
US$ 24.76
US$ 29.15
US$ 29.47
US$ 22.42
US$ 20.13
US$ 26.68
US$ 28.03
US$ 24.93
